1
|
Corbett KM, Ford L, Warren DB, Pouton CW, Chalmers DK. Cyclosporin Structure and Permeability: From A to Z and Beyond. J Med Chem 2021; 64:13131-13151. [PMID: 34478303 DOI: 10.1021/acs.jmedchem.1c00580] [Citation(s) in RCA: 35] [Impact Index Per Article: 11.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
Cyclosporins are natural or synthetic undecapeptides with a wide range of actual and potential pharmaceutical applications. Several members of the cyclosporin compound family have remarkably high passive membrane permeabilities that are not well-described by simple structural metrics. Here we review experimental studies of cyclosporin structure and permeability, including cyclosporin-metal complexes. We also discuss models for the conformation-dependent permeability of cyclosporins and similar compounds. Finally, we identify current knowledge gaps in the literature and provide recommendations regarding future avenues of exploration.
Collapse
Affiliation(s)
- Karen M Corbett
- Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, VIC 3052, Australia
| | - Leigh Ford
- Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, VIC 3052, Australia
| | - Dallas B Warren
- Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, VIC 3052, Australia
| | - Colin W Pouton
- Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, VIC 3052, Australia
| | - David K Chalmers
- Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, VIC 3052, Australia
| |
Collapse
|
2
|
Isidro-Llobet A, Kenworthy MN, Mukherjee S, Kopach ME, Wegner K, Gallou F, Smith AG, Roschangar F. Sustainability Challenges in Peptide Synthesis and Purification: From R&D to Production. J Org Chem 2019; 84:4615-4628. [PMID: 30900880 DOI: 10.1021/acs.joc.8b03001] [Citation(s) in RCA: 196] [Impact Index Per Article: 39.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
In recent years, there has been a growing interest in therapeutic peptides within the pharmaceutical industry with more than 50 peptide drugs on the market, approximately 170 in clinical trials, and >200 in preclinical development. However, the current state of the art in peptide synthesis involves primarily legacy technologies with use of large amounts of highly hazardous reagents and solvents and little focus on green chemistry and engineering. In 2016, the ACS Green Chemistry Institute Pharmaceutical Roundtable identified development of greener processes for peptide API as a critical unmet need, and as a result, a new Roundtable team formed to address this important area. The initial focus of this new team is to highlight best practices in peptide synthesis and encourage much needed innovations. In this Perspective, we aim to summarize the current challenges of peptide synthesis and purification in terms of sustainability, highlight possible solutions, and encourage synergies between academia, the pharmaceutical industry, and contract research organizations/contract manufacturing organizations.
Collapse
Affiliation(s)
- Albert Isidro-Llobet
- Medicines Research Centre , GlaxoSmithKline , Gunnels Wood Road , Stevenage SG1 2NY , U.K
| | - Martin N Kenworthy
- Pharmaceutical Technology and Development , AstraZeneca , Silk Road Business Park, Charter Way , Macclesfield SK10 2NA , U.K
| | - Subha Mukherjee
- Chemical and Synthetic Development , Bristol-Myers Squibb Company , One Squibb Drive , New Brunswick , New Jersey 08903 , United States
| | - Michael E Kopach
- Small Molecule Design and Development , Eli Lilly and Company , 1400 West Raymond Street , Indianapolis , Indiana , United States
| | - Katarzyna Wegner
- Active Pharmaceutical Ingredient Development , IPSEN Manufacturing Ireland, Ltd. , Blanchardstown Industrial Park , Dublin 15 , Ireland
| | - Fabrice Gallou
- Chemical & Analytical Development , Novartis , 4056 Basel , Switzerland
| | - Austin G Smith
- Drug Substance Process Development , Amgen, Inc. , 1 Amgen Center Drive , Thousand Oaks , California 91320 , United States
| | - Frank Roschangar
- Chemical Development , Boehringer Ingelheim Pharmaceuticals , Ridgefield , Connecticut 06877 , United States
| |
Collapse
|